CLVS - Clovis Oncology GAAP EPS of -$0.50 misses by $0.07 revenue of $32.14M misses by $4.94M
- Clovis Oncology press release ( NASDAQ: CLVS ): Q2 GAAP EPS of -$0.50 misses by $0.07 .
- Revenue of $32.14M (-12.7% Y/Y) misses by $4.94M .
- Clovis had $94.6M in cash and cash equivalents as of June 30, 2022.
- Cash used in operating activities down $23.4M or 40% in Q2 2022 compared to Q1 2022.
- Based on the company’s current cash, cash equivalents and liquidity available under its ATHENA clinical financing agreement, together with current estimates for revenues generated by sales of Rubraca, the company will need to raise additional capital in the near term in order to fund its operating plan and to continue as a going concern beyond February of 2023.
For further details see:
Clovis Oncology GAAP EPS of -$0.50 misses by $0.07, revenue of $32.14M misses by $4.94M